Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
The collaboration aims to bolster healthcare entrepreneurship
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Subscribe To Our Newsletter & Stay Updated
